Correct, trofinetide already has priority review. A priority review voucher can be awarded after NDA approval for use with another drug or to be sold on. Obviously the better outcome for Neuren would be for Acadia to sell the voucher.
- Forums
- ASX - By Stock
- NEU
- Acadia
Acadia, page-13
-
- There are more pages in this discussion • 665 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$19.91 |
Change
-0.030(0.15%) |
Mkt cap ! $2.544B |
Open | High | Low | Value | Volume |
$19.95 | $20.00 | $19.50 | $8.294M | 417.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 443 | $19.87 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.91 | 917 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 3395 | 19.750 |
3 | 6690 | 19.720 |
1 | 1119 | 19.710 |
1 | 1192 | 19.700 |
1 | 1119 | 19.670 |
Price($) | Vol. | No. |
---|---|---|
19.940 | 1119 | 1 |
19.960 | 528 | 1 |
19.980 | 1119 | 1 |
20.000 | 52 | 1 |
20.030 | 1119 | 1 |
Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online